首页|期刊导航|中国食品药品监管|药品委托生产监管的国际经验与中国实践

药品委托生产监管的国际经验与中国实践OA

International Experience and China's Practice in the Regulation of Pharmaceutical Contract Manufacturing

中文摘要英文摘要

药品上市许可持有人(MAH)制度实施以来,药品委托生产逐步成为我国医药产业专业化分工、创新成果转化和产能资源优化配置的重要组织形式.近年来,随着2019年修订的《中华人民共和国药品管理法》落地实施,以及 MAH 主体责任、委托生产监管、受托生产监管等核心要求的持续细化,加之2026年修订的《中华人民共和国药品管理法实施条例》正式施行,我国药品委托生产监管已从制度确立阶段进入责任细化、风险防控和质量能力提升并重的新阶段.与此同时,部分 MAH 主体责任落实仍需进一步细化,委托生产链条延伸,部分 MAH 质量管理体系建设和委托生产管理能力仍需提升,委托方与受托方质量管理体系衔接复杂,受托生产企业质量能力存在差异,跨区域监管协同和质量风险数据闭环仍需完善,也引发社会对药品质量责任落实、受托生产能力匹配、风险信息可追溯和跨区域监管协同的持续关切,对监管科学化、行业自律、质量文化建设和数智化治理提出了更高要求.本文在系统梳理美国、欧盟、日本、澳大利亚等主要监管体系经验基础上,结合我国近年来药品委托生产政策演进和实践现状,提出进一步完善制度实施评估与动态更新机制、健全委托方与受托方双向选择和持续管理机制、构建受托生产企业质量管理成熟度评价工具、强化质量文化建设、发挥行业组织和第三方评价作用、完善跨区域协同监管和风险数据闭环、以信息化为基础稳步推进数智赋能、推动专业化和国际化发展等思考,以期为我国药品委托生产高质量发展提供参考.

Since the implementation of the marketing authorization holder(MAH)system in China,contract manufacturing of pharmaceutical products has gradually become an important organizational form for the specialized division of labor in the pharmaceutical industry,the translation of innovative achievements,and the optimal allocation of production capacity resources.In recent years,with the implementation of the revised Drug Administration Law of the People's Republic of China(2019),the continuous refinement of core requirements concerning the MAH's primary responsibility,the regulation of contract manufacturing,and the oversight of contract manufacturers,as well as the formal implementation of the revised Regulations for the Implementation of the Drug Administration Law of the People's Republic of China(2026),the regulation of pharmaceutical contract manufacturing in China has entered a new stage characterized by the simultaneous emphasis on further refinement of responsibilities,risk prevention and control,and quality capability improvement,following the stage of institutional establishment.Meanwhile,the implementation of MAH primary responsibility still needs to be further refined;the contract manufacturing chain has continued to extend;the quality management system and contract manufacturing management capabilities of certain MAHs still need to be improved;the coordination between the quality management systems of entrusting and entrusted parties is complex;the quality capabilities of contract manufacturers vary;and cross-regional regulatory coordination and the closed-loop management of quality risk data still need to be improved.These issues have also given rise to continued public concern regarding the implementation of drug quality responsibilities,the matching of contract manufacturing capacities,the traceability of risk information,and cross-regional regulatory coordination,placing higher demands on regulatory science,industry self-regulation,quality culture development,and digital-intelligent governance.Based on a systematic review of the regulatory experiences of major jurisdictions,including the United States,the European Union,Japan,and Australia,and combined with the evolution of policies and the current practice of pharmaceutical contract manufacturing in China in recent years,this paper proposes the following considerations:further refining the mechanisms for implementation evaluation and dynamic updating of the system;strengthening the two-way selection and ongoing management mechanisms between entrusting and entrusted parties;developing a maturity assessment tool for the quality management systems of contract manufacturers;reinforcing quality culture development;leveraging the role of industry organizations and third-party evaluation;improving cross-regional coordinated regulation and the closed-loop management of risk data;steadily advancing digital-intelligent empowerment based on informatization;and promoting professionalization and internationalization,with a view to providing a reference for the high-quality development of pharmaceutical contract manufacturing in China.

袁林;刘钊

中国药品监督管理研究会国家药品监督管理局高级研修学院

医药卫生

药品委托生产药品上市许可持有人受托生产企业质量管理体系质量管理成熟度人工智能

pharmaceutical contract manufacturingmarketing authorization holdercontract manufacturerquality management systemquality management maturityartificial intelligence

《中国食品药品监管》 2026 (8)

18-31,14

10.3969/j.issn.1673-5390.2026.08.002

评论